How Long Does Semaglutide Last? Half-Life, Circulation, and Effect Duration
Direct answer: semaglutide has an elimination half-life of approximately one week in current U.S. product labeling. That does not mean the molecule is completely gone after seven days. Current labels report that semaglutide may remain in circulation for about five weeks after the last Ozempic or Rybelsus dose and about five to seven weeks after the last labeled Wegovy dose. “How long it lasts,” however, can mean half-life, measurable circulation, a dosing interval, or a clinical effect; those are not interchangeable.
Half-life is a rate, not an expiration time
An elimination half-life is the estimated time for a measured amount or concentration to decrease by half during the terminal elimination phase. After one half-life, approximately half remains; after another, approximately half of that remainder remains. The process is gradual, so a one-week half-life cannot be translated into “gone in one week.”
The current Ozempic DailyMed record reports an elimination half-life of approximately one week and presence in circulation for about five weeks after the last dose. The same molecular feature discussed in the semaglutide design guide—strong albumin binding supported by its fatty-acid side chain—helps reduce clearance and protect the peptide from degradation.
Product records give similar half-lives but different context
| Record | Reported half-life | Reported circulation after the last dose | What the record does not establish |
|---|---|---|---|
| Ozempic injection | Approximately 1 week | About 5 weeks | A universal assay-detection window or duration of every effect |
| Wegovy injection/tablet record | Approximately 1 week | About 5–7 weeks for the labeled presentations described in the record | That every semaglutide formulation has identical exposure |
| Rybelsus tablet | Approximately 1 week | About 5 weeks | Equivalence between an oral tablet and an unrelated material |
| Research semaglutide material | No duration can be assigned from the name alone | Requires a defined matrix, method, and study | Approved-product pharmacokinetics, clinical performance, or dosing instructions |
The current Wegovy DailyMed record reports approximately one week for elimination half-life and a five-to-seven-week circulation statement for its specified presentations. FDA’s Rybelsus prescribing information reports an approximately one-week half-life and about five weeks in circulation after the last dose.
The information gain from comparing these records is not that one number is “correct” and another is “wrong.” The records agree on the approximate half-life while attaching the longer circulation statement to specific finished products and studied conditions.
Detection time and effect duration require different evidence
“Present in circulation” is a pharmacokinetic label statement. A laboratory detection window additionally depends on specimen type, collection timing, analytical target, method sensitivity, calibration, and reporting threshold. A more sensitive assay can detect lower concentrations for longer, so detection is not a fixed synonym for half-life.
Clinical-effect duration is another question. Effects are measured with defined endpoints in defined populations and can be influenced by exposure, receptor biology, baseline characteristics, concomitant factors, and study design. A half-life can help explain sustained exposure, but it cannot by itself predict when a particular effect begins or ends for an individual.
This distinction also applies to material records. The semaglutide ingredients guide shows why the active molecule, excipients, and product form should be kept separate. The semaglutide refrigeration guide explains why one finished-product label cannot be applied to every material bearing the same peptide name.
For catalog navigation, use the Semaglutide research material and the broader GLP-1 Peptides collection. These pages do not convert approved-product pharmacokinetics into a claim about a catalog lot. Lot-specific analytical records belong in the COA library.
Research limitations
This article synthesizes current U.S. labeling and does not provide medical advice, a dosing schedule, or a prediction for an individual. Product labels can change, and the cited circulation statements apply to the named formulations and conditions. The article does not establish a detection window for a specific assay or measure semaglutide in a NEXTWAVE PEPTIDES batch.
Frequently asked questions
Does a one-week half-life mean semaglutide is gone after one week?
No. Half-life describes an approximate proportional decline. Current labels describe circulation for several weeks after the last dose.
Is “five weeks in circulation” the same as five weeks of clinical effect?
No. Circulation is a pharmacokinetic statement. Clinical-effect duration requires endpoint-specific evidence and cannot be read directly from the elimination half-life.
Can a laboratory always detect semaglutide for five weeks?
No universal detection window follows from the labels. Detectability depends on the specimen, analytical target, method sensitivity, collection schedule, and reporting threshold.
Does the same timeline apply to every semaglutide material?
No. The approximate half-life statements come from named approved-product records. An unrelated research material or formulation needs its own defined evidence.